The Company’s total revenues from operations stood at INR 726.40 Cr for the period ended 31st December 2018 as against INR 670.4 Cr for the same period last year, up by 8.35 percent year-on-year basis. However, the QoQ revenues declined by 2.33 percent (INR 743.80 Cr)

Sanofi India has reported a net income of INR 746.50 Cr for Q3 FY 2018-19, up by 8.41 percent year-on-year basis and decreased by 3.05 percent QoQ basis.

The Company’s total expenses stood at INR 615.70 Cr for October to December ’18 quarter, increased by 9.39 percent YoY basis and 5.69 percent QoQ basis.

The Company has reported a net profit (PAT) of INR 79.3 Cr as against INR 76 Cr for the same fiscal last year, up by 4.34 percent year-on-year basis, but the same was decreased by 33.47 percent (INR 119.2 Cr) QoQ basis.

The Board has recommended a final dividend of Rs. 66 per equity share of Rs. 10 for the year ended December 31, 2018. An interim dividend of Rs. 18 per equity share on Rs. 10 was paid in August 2018. The interim dividend and the proposed final dividend totaling to Rs. 84 per equity share of Rs. 10

The Basic and diluted earning per share (EPS) (not annualised) stood at 34.48 for the period ended 31st December 2018.

About Sanofi India Limited

Sanofi India Limited, formerly known as Aventis Pharma Limited, is amongst the leading multinational companies in the Indian Pharmaceutical Market.

History: Sanofi India was incorporated in May 1956 under the name Hoechst Fedco Pharma Private Limited. Over the years, its name was changed to Hoechst Pharmaceuticals Private Limited, Hoechst India Limited, Hoechst Marion Roussel Limited, Aventis Pharma Limited, and Sanofi India Limited.

Today, the Sanofi Company and its 100,000 employees are dedicated to making a difference in patients’ daily life, wherever they live and enable them to enjoy a healthier life.

Business: The Company offers innovative solutions in preventive healthcare (vaccines) as well as offers a wide array of medicines for therapy such as Diabetes, Cardiology, Thrombosis, Central Nervous System and Antihistamines.

Products: Sanofi India products viz. Amaryl, Combiflam, Lantus, and Allegra feature in the top 100 pharmaceutical brands in India. The products manufactured by the company are distributed in India and exported to many developed as well as developing countries, including Australia, Germany, the UK, Russia, and Italy.

Manufacturing Facility: The Company has its own manufacturing facility at (1) Ankleshwar, Gujarat, and (2) Goa.

Stock Price Movement

The stock ended 1.74% or Rs. 107.50 lower to INR 6068.60 on NSE when the market closed on Tuesday! During Q3 FY18-19, the share prices of Sanofi India has made a low of INR 5600 and high of INR 6480

Sanofi India on Technical Charts

Sanofi india ltd share price is trading 2.95% higher when compared to its 200 EMA (5895) and trading 2.55% lower when compared to its 50 EMA (6227)

Average Return

The stock has given almost no returns over the past 6 months and delivered 23.43% positive returns over the last 12 months.

Sanofi India current market cap is more than INR 14000 Cr and trading at a PE ratio of 37

Also Read

Finblab Value Pick Stock of the Month : KEI Industries Limited

Disclaimer: The contents and data presented here are just for your information & personal use only. While much effort is made to provide the information, I ( Vishal Dalwadi ) or “FinBlab” do not guarantee the accuracy, correctness, completeness or reliability of any information or data displayed herein and shall not be held responsible.

The post Sanofi India Limited: Result Update Q3FY19 appeared first on Upcoming ipos: Latest news on stocks, economy & finance.